CFTR Lifecycle Map—A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations

Different causative therapeutics for CF patients have been developed. There are still no mutation-specific therapeutics for some patients, especially those with rare CFTR mutations. For this purpose, high-throughput screens have been performed which result in various candidate compounds, with mostly...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinhoven, Liza, Stanke, Frauke, Hafkemeyer, Sylvia, Nietert, Manuel Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306775/
https://www.ncbi.nlm.nih.gov/pubmed/34299207
http://dx.doi.org/10.3390/ijms22147590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306775/
https://www.ncbi.nlm.nih.gov/pubmed/34299207
http://dx.doi.org/10.3390/ijms22147590

Ejemplares similares